Balkrishan Gill
Independent DirectorDr. Balkrishan Gill, also known as Simba, Ph.D., serves as an Executive Chairman at Serina Therapeutics, Inc. since April 12, 2024 and serves as its Co-Chairman of the Board since March 2026. He serves as an Independent Director at Foghorn Therapeutics Inc. since July 2017. He serves as an Independent Director at Sensorium Therapeutics, Inc. since January 2024 and serves as its Executive Chair since July 2025. He serves as Executive Chair at Blackfynn Inc. Dr. Gill is Venture Partner at Flagship Pioneering, Inc. since 2015. Dr. Gill has also served as a Senior Partner at Flagship Pioneering, Inc. He joined Flagship Pioneering in 2015 and focuses on providing strategic counsel and support to portfolio companies. Dr. Gill serves as Chief Executive Officer and President at Evelo Therapeutics, Inc. He served as Interim Principal Financial Officer of Evelo Biosciences, Inc. since June 3, 2022, until September 01, 2022. He served as Chief Executive Officer and President of Evelo Biosciences, Inc. from September 2015 until November 20, 2023 and served as its Treasurer since February 2020 until June 01, 2021. Dr. Gill served as Principal Financial Officer at Evelo Biosciences, Inc. since February 27, 2020, until June 01, 2021. He served as founding Executive Chair at Evelo Biosciences, Inc. from 2015 to 2023. He served as the Chief Executive Officer at Blackfynn Inc. Dr. Gill founded moksha8 Pharmaceuticals, Inc. and served as its Chief Executive Officer and President from 2006 to 2015. While at moksha8, he founded a biosimilar antibody company called fourteen22. Dr. Gill was an Entrepreneur in Residence and Venture Partner at TPG Growth/Texas Pacific Group Growth. He was involved in several of TPG's healthcare investments in the Emerging Markets including ShangPharma and Agria. Dr. Gill served as Special Advisor of Maxygen Inc. since December 2005. He was employed at Avidia. He was co head of Worldwide Marketing for Recormon. He also led corporate and market development and strategy from inception to commercialization of the Elecsys immunodiagnostics system. He served as an Executive Officer at Roche Diagnostics GmbH. Prior to joining TPG, Dr. Gill served as President at Maxygen Inc. from April 2000 to December 2005. Dr. Gill joined Maxygen Inc. in July 1998 and was its Chief Financial Officer from 1997 to 2006 and Senior Vice President of Business Development. Dr. Gill has previously led Corporate Development activities in a number of biotech companies and formed many significant strategic partnerships with several of the world's major pharmaceutical, agricultural and chemical companies including Roche, Pfizer, AstraZeneca, Novo, Novartis, Lundbeck and DuPont. Before joining Maxygen, Dr. Gill served as Vice President of Business Development at Valentis Inc. (a/k/a, Megabios Corp.), from November 1996 to July 1998. Dr. Gill began his career at Celltech, focused on antibody research. From November 1995 to November 1996, Dr. Gill served as Director of Business Development at Systemix Inc. Before joining Systemix, Dr. Gill held a variety of positions at Boehringer Mannheim, including Global Product Manager for erythropoietin, Manager of Corporate Business Development and Director of New Diagnostics Program Management. He also served as Global Marketing Director at Boehringer Mannheim (now Roche). He served as Independent Non Executive Director of PuriCore Plc (Realm Therapeutics Plc) since March 1, 2016 until July 31, 2019. He serves as a Director of Evelo Therapeutics, Inc. He served as a Director at Evelo Biosciences, Inc. since September 2015 until November 20, 2023. He served as a Director at Verdia Inc. moksha8 Pharmaceuticals Inc. and Codexis Inc. He has a long track record of identifying new technologies and geographies for high growth business opportunities. Dr. Gill received his Ph.D. in immunology and antibody engineering at King's College, London University in collaboration with the U.K. biotechnology company Celltech and his M.B.A. from INSEAD in Fontainbleau, France.
Positions
- Company NameFoghorn Therapeutics Inc.Stock CodeFHTXPositionIndependent DirectorColleagues
- DGDouglas G. ColeFounder & Independent Chairman of the Board
- AHAdrian H. B. GottschalkPresident, CEO & Director
- SFSteven F. BellonChief Scientific Officer
- AQAlfonso Quintas CardamaChief Medical Officer
- GRGerald R. CrabtreeFounder & Member of Scientific Advisory Board
- BLB. Lynne ParshallIndependent Director
- Company NameSerina Therapeutics, Inc.Stock CodeSERPositionExecutive Co-Chairman of the BoardColleagues
- BGBalkrishan GillExecutive Co-Chairman of the Board
- GHGregory H. BaileyIndependent Co-Chairman of the Board of Directors
- SASteven A. LedgerCEO & Director
- JMJ. Milton HarrisCo-Founder, Director Emeritus & Chair of Scientific Advisory Board
- STSrini TenjarlaChief Technical Operations Officer
- RWRandall W. MoreadithChief Development Officer
- KJKaren J. WilsonIndependent Director
